Business
Mesoblast sees lasting need for COVID treatment beyond a vaccine – Sydney Morning Herald
The next two months will be hugely important for the stem cell therapy company’s research projects, and its growth prospects as it works on a product to treat the deadly disease.
Mesoblast is hoping its flagship product remestemcel-L will be shown to relieve acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company is running a phase 3 trial of the product in US hospitals, but the research is still in its early stages, with a pilot study of the project looking at only 12 patients.
The US Data Safety Monitoring board, which reviews clinical data, had selected a date in early September to complete an initial review of Mesoblast’s phase 3 trial, the comp…
-
General16 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
General10 hours agoInternal Revenue Service starts cutting 20,000 workers